All Thrombosis Research

  • Navarese EP, Wernly B, Lichtenauer M, Petrescu AM, Kołodziejczak M, Lauten A, Frediani L, Veulemanns V, Wanha W, Wojakowski W, Lesiak M, Ferrante G, Zeus T, Tantry U, Bliden K, Buffon A, Contegiacomo G, Jung C, Kubica J, Pestrichella V, Gurbel PA. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol. 2018 Jul 3.
  • Giustino G, Redfors B, Kirtane AJ, Mehran R, Dangas GD, Witzenbichler B, Neumann FJ, Weisz G, Généreux P, Maehara A, McAndrew T, Farhan S, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Gurbel P, Ben-Yehuda O, Stone GW. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. JACC Cardiovasc Interv. 2018 Jun 8
  • Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thromb Haemost. 2018 Jun 4
  • Beckhoff F, Alushi B, Jung C, Navarese E, Franz M, Kretzschmar D, Wernly B, Lichtenauer M, Lauten A. Tricuspid Regurgitation - Medical Management and Evolving Interventional Concepts. Front Cardiovasc Med. 2018 May 28;5:49
  • Navarese EP, Kołodziejczak M, Petrescu A, Wernly B, Lichtenauer M, Lauten A, Buffon A, Wanha W, Pestrichella V, Sardella G, Contegiacomo G, Tantry U, Bliden K, Kubica J, Gurbel PA. Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2018 May 8.
  • Gurbel PA, Tantry US, D'Andrea D, Chung T, Alexander JH, Bliden KP, Wright SD, Tricoci P. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. J Thromb Thrombolysis. 2018 Mar 26.
  • Mahla E, Metzler H, Bornemann-Cimenti H, Prueller F, Raggam RB, Pregartner G, Berghold A, Baumann A, Goeroeg C, Gurbel PA. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study. Thromb Haemost. 2018 Apr 6.
  • Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 Apr 5.
  • Tantry US, Navarese EP, Myat A, Chaudhary R, Gurbel PA. Combination Oral Antithrombotic Therapy for the Treatment of Myocardial Infarction: Recent Developments. Expert Opin Pharmacother. 2018 Apr 3.
  • Navarese EP, Wernly B, Lichtenauer M, Pepe M, Wanha W, Ferrante G, Frediani L, Veulemans V, Zeus T, Westenfeld R, Jung C, Gurbel PA. Prime time for the sweet spot in timing of coronary invasive approach in patients with non-ST elevation myocardial infarction. J Thorac Dis. 2018 Jan;10(1):17-20.
  • Andreotti F, Navarese EP, Crea F. Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes. Eur Heart J. 2018 Apr 1;39(13):1086-1088.
  • Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1566-1579
  • Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018 Apr; 198:152-159
  • Wolff G, Navarese EP, Brockmeyer M, Lin Y, Karathanos A, Kołodziejczak M, Kubica J, Polzin A, Zeus T, Westenfeld R, Andreotti F, Kelm M, Schulze V. Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2018 May 1;258:59-67
  • Chaudhary R, Garg J, Krishnamoorthy P, Bliden K, Shah N, Agarwal N, Gupta R, Sharma A, Kern KB, Patel NC, Gurbel P. Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. World J Cardiol. 2017 Dec 26;9(12):830-837.
  • Bae JS, Ahn JH, Tantry U, Gurbel PA, Jeong YH. Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Focused on ACS or PCI-treated Patients. Curr Vasc Pharmacol. 2018 Jan 16.
  • Tantry U, Navarese EP, Myat A, Gurbel P. Selection of P2Y(12) inhibitor in percutaneous coronary intervention and/or acute coronary syndrome. Prog Cardiovasc Dis. 2018 Jan 12
  • Jeong YH, Bae JS, Gurbel PA. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018 Jan 25;378(4):396
  • Kolodziejczak M, Andreotti F, Navarese EP. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. Ann Intern Med. 2018 Feb 6;168(3):234-235.
  • P, Kolodziejczak M, Anisimowicz L, Kubica J, Navarese EP, Kowalewski M; SIRIO-TAVI group. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017 Sep 8
  • Kubica J, Adamski P, Buszko K, Kubica A, Kuliczkowski W, Fabiszak T, Jilma B, Alexopoulos D, Paciorek P, Navarese EP. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2017 Oct 10.
  • Gurbel PA, Bliden KP, Zhu J, Troullos E, Centofanti R, Jarvis S, Venkataraman P, Tantry US. Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis. 2017 Dec 2.
  • Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol. 2017 Dec 16
  • Venkataraman G, Bliden KP, Tantry US, Gurbel PA. Thromboembolism after WATCHMAN(TM) in a clopidogrel non-responder: A case for concern? Catheter Cardiovasc Interv. 2017 Nov 11.
  • Bliden KP, Chaudhary R, Navarese EP, Sharma T, Kaza H, Tantry US, Gurbel PA. Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. 2017 Nov 20; 268:55-62.
  • Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies. Circulation. 2017 Oct 30.
  • Gurbel PA, Navarese EP, Tantry US. Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet? J Am Coll Cardiol. 2017 Sep 19;70(12):1463-1466
  • Chaudhary R, Mathew D, Bliden K, Tantry US, Sharma T, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Gurbel PA. LDL(4): a novel predictor of coronary artery disease severity. Curr Med Res Opin. 2017 Aug 8:1-17
  • Navarese EP, Tijssen JGP. Striking the Balance Between Benefits and Costs of Ticagrelor Beyond 1 Year After Myocardial Infarction. J Am Coll Cardiol. 2017 Aug 1;70(5):539-541
  • Tantry US, Jeong YH, Gurbel PA. More Evidence for Non-P2Y(12)-Mediated Effects of Ticagrelor. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1659-1661
  • Chen G, Bliden KP, Chaudhary R, Liu F, Kaza H, Navarese EP, Tantry US, Gurbel PA. Central aortic pulse pressure, thrombogenicity and cardiovascular risk. J Thromb Thrombolysis. 2017 Jul 10
  • Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Gurbel PA, Mehran R, Généreux P, Ben-Yehuda O, Simonton CA, Stone GW; ADAPT-DES Investigators. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated with Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017 Jul 27
  • Kolodziejczak M, Andreotti F, Kowalewski M, Buffon A, Ciccone MM, Parati G, Scicchitano P, Uminska JM, De Servi S, Bliden KP, Kubica J, Bortone A, Crea F, Gurbel P, Navarese EP. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients with Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Ann Intern Med. 2017 Jul 18;167(2):103-111.
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 May;43(4):437-445.
  • Shah P, Tantry US, Bliden KP, Gurbel PA. Bleeding and thrombosis associated with ventricular assist device therapy. J Heart Lung Transplant. 2017 May 11.
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121
  • Ahn JH, Gurbel PA, Jeong YH. Ticagrelor versus Clopidogrel in Peripheral Artery Disease. N Engl J Med. 2017 Apr 13;376(15):1487-8
  • Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017 Mar 17.
  • Gurbel PA, Price MJ, Dahlen JR, Tantry US. ANTARCTIC: platelet function testing to adjust therapy. Lancet. 2017 Mar 25;389(10075):1193
  • Koh JS, Park Y, Tantry US, Ahn JH, Kang MG, Kim K, Jang JY, Park HW, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets. 2017 Mar;28(2):187-193
  • Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S,Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M,Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O' Connor C, Strippoli GF. Prevention of contrast-induced acute kidney injury in patientsundergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One. 2017 Feb 2;12(2)
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 Feb 28
  • Park Y, Tantry US, Koh JS, Ahn JH, Kang MG, Kim KH, Jang JY, Park HW, Park JR,Hwang SJ, Park KS, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Novel role of platelet reactivity in adverse left ventricular remodeling after ST-segment elevation myocardial infarction: The REMODELING Trial. Thromb Haemost. 2017 Feb 2.
  • Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017 Feb 15.
  • Tantry US, Gurbel PA. Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. Circ Cardiovasc Interv. 2017 Feb;10(2).
  • Gurbel PA, deFilippi CR, Bliden KP, Tantry US. HIV infection, ACS, PCI andhigh platelet reactivity: ingredients for a perfect thrombotic storm. Eur HeartJ. 2017 Jan 12
  • Sharma T, Bliden K, Chaudhary R, Tantry U, Gurbel PA. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opin Pharmacother. 2017 Jan;18(1):123-131.
  • Kim JH, Shah P, Tantry US, Gurbel PACoagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. Curr Heart Fail Rep. 2016 Nov 4.
  • Gurbel PA, Tantry USAntiplatelet therapy: What have we learned from the ANTARCTIC trial?Nat Rev Cardiol. 2016 Nov;13(11):639-640.
  • Cornel JH, Ohman EM, Neely B, Jakubowski JA, Bhatt DL, White HD, Ardissino D, Fox KA, Prabhakaran D, Armstrong PW, Erlinge D, Tantry US, Gurbel PA, Roe MT. Relationship of Platelet Reactivity with Bleeding Outcomes During Long-Term Treatment with Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.J Am Heart Assoc.2016 Nov 4;5(11).
  • Gurbel PA, Bliden KP, Tantry US, Monroe AL, Muresan AA, Brunner NE, Lopez-Espina CG, Delmenico PR, Cohen E, Raviv G, Haugen DL, Ereth MH. First report of the point-of-care TEG: A technical validation study of the TEG-6S system.2016 Nov;27(7):642-649.
  • Myat A, Tantry US, Kubica J, Gurbel PACurrent controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Rev Cardiovasc Ther. 2016 Nov 2:1-10.
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Am J Cardiovasc Drugs. 2016 Nov 17
  • Gurbel PA, Bliden KP, Baker BA, Dahlen J, Tantry US.Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2364
  • Chaudhary R, Saadin K, Bliden KP, Harris WS, Dinh B, Sharma T, Tantry US, Gurbel PARisk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2016 Oct113:40-45.
  • Gurbel PA, Jeong YH, Tantry UThe Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition? 2016 Oct 27
  • Chaudhary R, Bliden KP, Garg J, Mohammed N, Tantry U, Mathew D, Toth PP, Franzese C, Gesheff M, Pandya S, Gurbel PStatin therapy and inflammation in patients with diabetes treated with high dose aspirin.J Diabetes Complications 2016 Sep-Oct;30(7):1365-70.
  • Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, Siller-Matula JM, Dąbrowska A, Fabiszak T, Koziński M, Gurbel PA.Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016 Jul 15; 215:201-8.
  • Gurbel P et al. First report of the point-of-care TEG: A technical validation study of the TEG-6S system. Platelets 2016
  • Gurbel P et al. Platelet inhibitors and their differences.European Heart Journal. 2016; 37:323-326
  • Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E, Toller W, Berghold A, Tantry US, Gurbel PADoes Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? Ann Thorac Surg. 2016 Jul 1
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PAExtended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91.
  • Mahla E, Tantry US, Gurbel PA. To stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?J Thorac Dis. 2016 Jul;8(7):E578-80
  • Gurbel, PA, Tantry, USAntiplatelet therapy for Non-St-segment elevation acute coronary syndromes; Acute coronary syndrome- Coronary artery disease. ACCSAP 9. Eds: Patrick T. O’Gara. American College of Cardiology 2016
  • Gurbel PA, Tantry USAntithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 2016 Jun 1;102(11):882-92.
  • Bedeir K, Bliden K, Tantry U, Gurbel PA, Mahla E. Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. Can J Cardiol.2016 Jun;32(6):724-5.
  • Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study.Am J Cardiol. 2016 Jun 15;117(12):1877-83
  • Bliden KP, Chaudhary R, Lopez LR, Damrongwatanasuk R, Guyer K, Gesheff MG, Franzese CJ, Kaza H, Tantry US, Gurbel PAOxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. Am J Cardiol. 2016 Jun 15.
  • Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PAProprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med.2016 May 3;164(9):600-7
  • Kwon TJ, Tantry US, Park Y, Choi YM, Ahn JH, Kim KH, Koh JS, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Smith SC Jr, Jeong YH. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost. 2016 May 2;115(5):979-92
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PAExtended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascularevents. Expert Rev Cardiovasc Ther. 2016 May 23.
  • Reny JL, Fontana P, Hochholzer W, Neumann FJ, Ten Berg J, Janssen PW, Geisler T, Gawaz M, Marcucci R, Gori AM, Cuisset T, Alessi MC, Berdagué P, Gurbel PA, Yong G, Angiolillo DJ, Aradi D, Beigel R, Campo G, Combescure C. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb Haemost. 2016 Apr;115(4):844-55.
  • Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside.Circ Res. 2016 Apr 29;118(9):1380-91.
  • Bliden KP, Tantry US, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Mathew DP, Chaudhary R, Gurbel PAThrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.J Interv Cardiol. 2016 Apr;29(2):168-78.
  • Gurbel PA, Tantry USDeciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. Eur Heart J. 2016 Apr 7;37(14):1143-4
  • Bliden KP, Tantry US, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Mathew DP, Chaudhary R,
  • Chaudhary R, Bliden KP, Tantry US, Mohammed N, Mathew D, Gesheff MG, Franzese CJ, Gurbel PAAssociation of weight gain with coronary artery disease, inflammation and thrombogenicity.J Thromb Thrombolysis. 2016 Apr;41(3):394-403
  • Gurbel PA, Tantry USDeciding about prolonged ticagrelor therapy in coronaryclot formers: an ongoing dilemma. Eur Heart J. 2016 Apr 7;37(14):1143-4.
  • King K, Grazette LP, Paltoo DN, McDevitt JT, Sia SK, Barrett PM, Apple FS, Gurbel PA, Weissleder R, Leeds H, Iturriaga EJ, Rao A, Adhikari B, Desvigne-Nickens P, Galis ZS, Libby P. Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci. 2016 Jan-Feb;1(1-2):73-86.
  • Gurbel PA, Tantry USCardioPulse: Platelet inhibitors and their differences. Eur Heart J. 2016 Jan 21;37(4):323-6
  • Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol.2016 Jan;36(1):189-97.

Dr. Paul Gurbel

  • Navarese EP, Wernly B, Lichtenauer M, Petrescu AM, Kołodziejczak M, Lauten A, Frediani L, Veulemanns V, Wanha W, Wojakowski W, Lesiak M, Ferrante G, Zeus T, Tantry U, Bliden K, Buffon A, Contegiacomo G, Jung C, Kubica J, Pestrichella V, Gurbel PA. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol. 2018 Jul 3.
  • Giustino G, Redfors B, Kirtane AJ, Mehran R, Dangas GD, Witzenbichler B, Neumann FJ, Weisz G, Généreux P, Maehara A, McAndrew T, Farhan S, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Gurbel P, Ben-Yehuda O, Stone GW. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. JACC Cardiovasc Interv. 2018 Jun 8
  • Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thromb Haemost. 2018 Jun 4
  • Navarese EP, Kołodziejczak M, Petrescu A, Wernly B, Lichtenauer M, Lauten A, Buffon A, Wanha W, Pestrichella V, Sardella G, Contegiacomo G, Tantry U, Bliden K, Kubica J, Gurbel PA. Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2018 May 8.
  • Gurbel PA, Tantry US, D'Andrea D, Chung T, Alexander JH, Bliden KP, Wright SD, Tricoci P. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. J Thromb Thrombolysis. 2018 Mar 26.
  • Mahla E, Metzler H, Bornemann-Cimenti H, Prueller F, Raggam RB, Pregartner G, Berghold A, Baumann A, Goeroeg C, Gurbel PA. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study. Thromb Haemost. 2018 Apr 6.
  • Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 Apr 5.
  • Tantry US, Navarese EP, Myat A, Chaudhary R, Gurbel PA. Combination Oral Antithrombotic Therapy for the Treatment of Myocardial Infarction: Recent Developments. Expert Opin Pharmacother. 2018 Apr 3.
  • Navarese EP, Wernly B, Lichtenauer M, Pepe M, Wanha W, Ferrante G, Frediani L, Veulemans V, Zeus T, Westenfeld R, Jung C, Gurbel PA. Prime time for the sweet spot in timing of coronary invasive approach in patients with non-ST elevation myocardial infarction. J Thorac Dis. 2018 Jan;10(1):17-20.
  • Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1566-1579
  • Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018 Apr; 198:152-159
  • Chaudhary R, Garg J, Krishnamoorthy P, Bliden K, Shah N, Agarwal N, Gupta R, Sharma A, Kern KB, Patel NC, Gurbel P. Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. World J Cardiol. 2017 Dec 26;9(12):830-837.
  • Bae JS, Ahn JH, Tantry U, Gurbel PA, Jeong YH. Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Focused on ACS or PCI-treated Patients. Curr Vasc Pharmacol. 2018 Jan 16.
  • Tantry U, Navarese EP, Myat A, Gurbel P. Selection of P2Y(12) inhibitor in percutaneous coronary intervention and/or acute coronary syndrome. Prog Cardiovasc Dis. 2018 Jan 12
  • Jeong YH, Bae JS, Gurbel PA. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018 Jan 25;378(4):396
  • Gurbel PA, Bliden KP, Zhu J, Troullos E, Centofanti R, Jarvis S, Venkataraman P, Tantry US. Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis. 2017 Dec 2.
  • Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol. 2017 Dec 16
  • Venkataraman G, Bliden KP, Tantry US, Gurbel PA. Thromboembolism after WATCHMAN(TM) in a clopidogrel non-responder: A case for concern? Catheter Cardiovasc Interv. 2017 Nov 11.
  • Bliden KP, Chaudhary R, Navarese EP, Sharma T, Kaza H, Tantry US, Gurbel PA. Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. 2017 Nov 20; 268:55-62.
  • Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies. Circulation. 2017 Oct 30.
  • Gurbel PA, Navarese EP, Tantry US. Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet? J Am Coll Cardiol. 2017 Sep 19;70(12):1463-1466
  • Chaudhary R, Mathew D, Bliden K, Tantry US, Sharma T, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Gurbel PA. LDL(4): a novel predictor of coronary artery disease severity. Curr Med Res Opin. 2017 Aug 8:1-17
  • Tantry US, Jeong YH, Gurbel PA. More Evidence for Non-P2Y(12)-Mediated Effects of Ticagrelor. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1659-1661
  • Chen G, Bliden KP, Chaudhary R, Liu F, Kaza H, Navarese EP, Tantry US, Gurbel PA. Central aortic pulse pressure, thrombogenicity and cardiovascular risk. J Thromb Thrombolysis. 2017 Jul 10
  • Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Gurbel PA, Mehran R, Généreux P, Ben-Yehuda O, Simonton CA, Stone GW; ADAPT-DES Investigators. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017 Jul 27
  • Kolodziejczak M, Andreotti F, Kowalewski M, Buffon A, Ciccone MM, Parati G, Scicchitano P, Uminska JM, De Servi S, Bliden KP, Kubica J, Bortone A, Crea F, Gurbel P, Navarese EP. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients with Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Ann Intern Med. 2017 Jul 18;167(2):103-111.
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 May;43(4):437-445.
  • Shah P, Tantry US, Bliden KP, Gurbel PA. Bleeding and thrombosis associated with ventricular assist device therapy. J Heart Lung Transplant. 2017 May 11.
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121
  • Ahn JH, Gurbel PA, Jeong YH. Ticagrelor versus Clopidogrel in Peripheral Artery Disease. N Engl J Med. 2017 Apr 13;376(15):1487-8
  • Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017 Mar 17.
  • Gurbel PA, Price MJ, Dahlen JR, Tantry US. ANTARCTIC: platelet function testing to adjust therapy. Lancet. 2017 Mar 25;389(10075):1193
  • Koh JS, Park Y, Tantry US, Ahn JH, Kang MG, Kim K, Jang JY, Park HW, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets. 2017 Mar;28(2):187-193
  • Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S,Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M,Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O' Connor C, Strippoli GF. Prevention of contrast-induced acute kidney injury in patientsundergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One. 2017 Feb 2;12(2)
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 Feb 28
  • Park Y, Tantry US, Koh JS, Ahn JH, Kang MG, Kim KH, Jang JY, Park HW, Park JR,Hwang SJ, Park KS, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Novel role of platelet reactivity in adverse left ventricular remodeling after ST-segment elevation myocardial infarction: The REMODELING Trial. Thromb Haemost. 2017 Feb 2.
  • Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017 Feb 15.
  • Tantry US, Gurbel PA. Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. Circ Cardiovasc Interv. 2017 Feb;10(2).
  • Gurbel PA, deFilippi CR, Bliden KP, Tantry US. HIV infection, ACS, PCI andhigh platelet reactivity: ingredients for a perfect thrombotic storm. Eur HeartJ. 2017 Jan 12
  • Sharma T, Bliden K, Chaudhary R, Tantry U, Gurbel PA. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opin Pharmacother. 2017 Jan;18(1):123-131.
  • Kim JH, Shah P, Tantry US, Gurbel PACoagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. Curr Heart Fail Rep. 2016 Nov 4.
  • Gurbel PA, Tantry USAntiplatelet therapy: What have we learned from the ANTARCTIC trial?Nat Rev Cardiol. 2016 Nov;13(11):639-640.
  • Cornel JH, Ohman EM, Neely B, Jakubowski JA, Bhatt DL, White HD, Ardissino D, Fox KA, Prabhakaran D, Armstrong PW, Erlinge D, Tantry US, Gurbel PA, Roe MT. Relationship of Platelet Reactivity with Bleeding Outcomes During Long-Term Treatment with Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.J Am Heart Assoc.2016 Nov 4;5(11).
  • Gurbel PA, Bliden KP, Tantry US, Monroe AL, Muresan AA, Brunner NE, Lopez-Espina CG, Delmenico PR, Cohen E, Raviv G, Haugen DL, Ereth MH. First report of the point-of-care TEG: A technical validation study of the TEG-6S system.2016 Nov;27(7):642-649.
  • Myat A, Tantry US, Kubica J, Gurbel PACurrent controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Rev Cardiovasc Ther. 2016 Nov 2:1-10.
  • Bliden KP, Tantry US, Chaudhary R, Gurbel PA. Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91..
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Am J Cardiovasc Drugs. 2016 Nov 17
  • Gurbel PA, Bliden KP, Baker BA, Dahlen J, Tantry US.Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2364
  • Chaudhary R, Saadin K, Bliden KP, Harris WS, Dinh B, Sharma T, Tantry US, Gurbel PARisk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2016 Oct113:40-45.
  • Gurbel PA, Jeong YH, Tantry UThe Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition? 2016 Oct 27
  • Chaudhary R, Bliden KP, Garg J, Mohammed N, Tantry U, Mathew D, Toth PP, Franzese C, Gesheff M, Pandya S, Gurbel PStatin therapy and inflammation in patients with diabetes treated with high dose aspirin.J Diabetes Complications 2016 Sep-Oct;30(7):1365-70.
  • Gurbel P et al. First report of the point-of-care TEG: A technical validation study of the TEG-6S system. Platelets 2016
  • Gurbel P et al. Platelet inhibitors and their differences.European Heart Journal. 2016; 37:323-326
  • Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E, Toller W, Berghold A, Tantry US, Gurbel PADoes Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? Ann Thorac Surg. 2016 Jul 1
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PAExtended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91.
  • Mahla E, Tantry US, Gurbel PATo stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us? J Thorac Dis.2016 Jul;8(7):
  • Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, Siller-Matula JM, Dąbrowska A, Fabiszak T, Koziński M, Gurbel PAImpact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.Int J Cardiol. 2016 Jul 15; 215:201-8
  • Gurbel, PA, Tantry, USAntiplatelet therapy for Non-St-segment elevation acute coronary syndromes; Acute coronary syndrome- Coronary artery disease. ACCSAP 9. Eds: Patrick T. O’Gara. American College of Cardiology 2016
  • Gurbel PA, Tantry USAntithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 2016 Jun 1;102(11):882-92
  • Bedeir K, Bliden K, Tantry U, Gurbel PA, Mahla E. Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. Can J Cardiol.2016 Jun;32(6):724-5.
  • Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk:From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.Am J Cardiol. 2016 Jun 15;117(12):1877-83
  • Bliden KP, Chaudhary R, Lopez LR, Damrongwatanasuk R, Guyer K, Gesheff MG, Franzese CJ, Kaza H, Tantry US, Gurbel PAOxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. Am J Cardiol. 2016 Jun 15.
  • Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PAProprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med.2016 May 3;164(9):600-7
  • Kwon TJ, Tantry US, Park Y, Choi YM, Ahn JH, Kim KH, Koh JS, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Smith SC Jr, Jeong YH. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost. 2016 May 2;115(5):979-92
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PAExtended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascularevents. Expert Rev Cardiovasc Ther. 2016 May 23.
  • Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside.Circ Res. 2016 Apr 29;118(9):1380-91.
  • Bliden KP, Tantry US, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Mathew DP, Chaudhary R, Gurbel PAThrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.J Interv Cardiol. 2016 Apr;29(2):168-78.
  • Chaudhary R, Bliden KP, Tantry US, Mohammed N, Mathew D, Gesheff MG, Franzese CJ, Gurbel PA.Association of weight gain with coronary artery disease, inflammation and thrombogenicity. J Thromb Thrombolysis. 2016 Apr;41(3):394-403.
  • Reny JL, Fontana P, Hochholzer W, Neumann FJ, Ten Berg J, Janssen PW, Geisler T, Gawaz M, Marcucci R, Gori AM, Cuisset T, Alessi MC, Berdagué P, Gurbel PA, Yong G, Angiolillo DJ, Aradi D, Beigel R, Campo G, Combescure C. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.Thromb Haemost. 2016 Apr;115(4):844-55
  • Gurbel PA, Jeong YH,Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside.Circ Res. 2016 Apr 29;118(9):1380-91.
  • Gurbel PA, Tantry USDeciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. Eur Heart J. 2016 Apr 7;37(14):1143-4
  • King K, Grazette LP, Paltoo DN, McDevitt JT, Sia SK, Barrett PM, Apple FS, Gurbel PA, Weissleder R, Leeds H, Iturriaga EJ, Rao A, Adhikari B, Desvigne-Nickens P, Galis ZS, Libby P. Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci. 2016 Jan-Feb;1(1-2):73-86.
  • Gurbel PA, Tantry USCardioPulse: Platelet inhibitors and their differences. Eur Heart J. 2016 Jan 21;37(4):323-6
  • Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol.2016 Jan;36(1):189-97.

Udaya Tantry, PhD

  • Navarese EP, Wernly B, Lichtenauer M, Petrescu AM, Kołodziejczak M, Lauten A, Frediani L, Veulemanns V, Wanha W, Wojakowski W, Lesiak M, Ferrante G, Zeus T, Tantry U, Bliden K, Buffon A, Contegiacomo G, Jung C, Kubica J, Pestrichella V, Gurbel PA. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol. 2018 Jul 3.
  • Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thromb Haemost. 2018 Jun 4
  • Navarese EP, Kołodziejczak M, Petrescu A, Wernly B, Lichtenauer M, Lauten A, Buffon A, Wanha W, Pestrichella V, Sardella G, Contegiacomo G, Tantry U, Bliden K, Kubica J, Gurbel PA. Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2018 May 8.
  • Gurbel PA, Tantry US, D'Andrea D, Chung T, Alexander JH, Bliden KP, Wright SD, Tricoci P. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. J Thromb Thrombolysis. 2018 Mar 26.
  • Bae JS, Ahn JH, Tantry U, Gurbel PA, Jeong YH. Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Focused on ACS or PCI-treated Patients. Curr Vasc Pharmacol. 2018 Jan 16.
  • Tantry U, Navarese EP, Myat A, Gurbel P. Selection of P2Y(12) inhibitor in percutaneous coronary intervention and/or acute coronary syndrome. Prog Cardiovasc Dis. 2018 Jan 12
  • Venkataraman G, Bliden KP, Tantry US, Gurbel PA. Thromboembolism after WATCHMAN(TM) in a clopidogrel non-responder: A case for concern? Catheter Cardiovasc Interv. 2017 Nov 11.
  • Bliden KP, Chaudhary R, Navarese EP, Sharma T, Kaza H, Tantry US, Gurbel PA. Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. 2017 Nov 20; 268:55-62.
  • Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies. Circulation. 2017 Oct 30.
  • Gurbel PA, Navarese EP, Tantry US. Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet? J Am Coll Cardiol. 2017 Sep 19;70(12):1463-1466
  • Chaudhary R, Mathew D, Bliden K, Tantry US, Sharma T, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Gurbel PA. LDL(4): a novel predictor of coronary artery disease severity. Curr Med Res Opin. 2017 Aug 8:1-17
  • Tantry US, Jeong YH, Gurbel PA. More Evidence for Non-P2Y(12)-Mediated Effects of Ticagrelor. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1659-1661
  • Chen G, Bliden KP, Chaudhary R, Liu F, Kaza H, Navarese EP, Tantry US, Gurbel PA. Central aortic pulse pressure, thrombogenicity and cardiovascular risk. J Thromb Thrombolysis. 2017 Jul 10
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 May;43(4):437-445.
  • Shah P, Tantry US, Bliden KP, Gurbel PA. Bleeding and thrombosis associated with ventricular assist device therapy. J Heart Lung Transplant. 2017 May 11.
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121
  • Ahn JH, Gurbel PA, Jeong YH. Ticagrelor versus Clopidogrel in Peripheral Artery Disease. N Engl J Med. 2017 Apr 13;376(15):1487-8
  • Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017 Mar 17.
  • Gurbel PA, Price MJ, Dahlen JR, Tantry US. ANTARCTIC: platelet function testing to adjust therapy. Lancet. 2017 Mar 25;389(10075):1193
  • Koh JS, Park Y, Tantry US, Ahn JH, Kang MG, Kim K, Jang JY, Park HW, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets. 2017 Mar;28(2):187-193
  • Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 Feb 28
  • Park Y, Tantry US, Koh JS, Ahn JH, Kang MG, Kim KH, Jang JY, Park HW, Park JR,Hwang SJ, Park KS, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Novel role of platelet reactivity in adverse left ventricular remodeling after ST-segment elevation myocardial infarction: The REMODELING Trial. Thromb Haemost. 2017 Feb 2.
  • Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017 Feb 15.
  • Tantry US, Gurbel PA. Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. Circ Cardiovasc Interv. 2017 Feb;10(2).
  • Gurbel PA, deFilippi CR, Bliden KP, Tantry US. HIV infection, ACS, PCI andhigh platelet reactivity: ingredients for a perfect thrombotic storm. Eur HeartJ. 2017 Jan 12
  • Sharma T, Bliden K, Chaudhary R, Tantry U, Gurbel PA. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opin Pharmacother. 2017 Jan;18(1):123-131.
  • Kim JH, Shah P, Tantry US, Gurbel PACoagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. Curr Heart Fail Rep. 2016 Nov 4.
  • Gurbel PA, Tantry USAntiplatelet therapy: What have we learned from the ANTARCTIC trial?Nat Rev Cardiol. 2016 Nov;13(11):639-640.
  • Cornel JH, Ohman EM, Neely B, Jakubowski JA, Bhatt DL, White HD, Ardissino D, Fox KA, Prabhakaran D, Armstrong PW, Erlinge D, Tantry US, Gurbel PA, Roe MT. Relationship of Platelet Reactivity with Bleeding Outcomes During Long-Term Treatment with Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.J Am Heart Assoc.2016 Nov 4;5(11).
  • Gurbel PA, Bliden KP, Tantry US, Monroe AL, Muresan AA, Brunner NE, Lopez-Espina CG, Delmenico PR, Cohen E, Raviv G, Haugen DL, Ereth MH. First report of the point-of-care TEG: A technical validation study of the TEG-6S system.2016 Nov;27(7):642-649.
  • Myat A, Tantry US, Kubica J, Gurbel PACurrent controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Rev Cardiovasc Ther. 2016 Nov 2:1-10.
  • Bliden KP, Tantry US, Chaudhary R, Gurbel PA. Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91..
  • Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Am J Cardiovasc Drugs. 2016 Nov 17
  • Gurbel PA, Bliden KP, Baker BA, Dahlen J, Tantry US.Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2364
  • Chaudhary R, Saadin K, Bliden KP, Harris WS, Dinh B, Sharma T, Tantry US, Gurbel PARisk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2016 Oct113:40-45.
  • Gurbel PA, Jeong YH, Tantry UThe Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition? 2016 Oct 27
  • Chaudhary R, Bliden KP, Garg J, Mohammed N, Tantry U, Mathew D, Toth PP, Franzese C, Gesheff M, Pandya S, Gurbel PStatin therapy and inflammation in patients with diabetes treated with high dose aspirin.J Diabetes Complications 2016 Sep-Oct;30(7):1365-70.
  • Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E, Toller W, Berghold A, Tantry US, Gurbel PADoes Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? Ann Thorac Surg. 2016 Jul 1
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PA.Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91.
  • Mahla E, Tantry US, Gurbel PA. To stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?J Thorac Dis. 2016 Jul;8(7): E578-80
  • Gurbel, PA, Tantry, USAntiplatelet therapy for Non-St-segment elevation acute coronary syndromes; Acute coronary syndrome- Coronary artery disease. ACCSAP 9. Eds: Patrick T. O’Gara. American College of Cardiology 2016
  • Gurbel PA, Tantry USAntithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 2016 Jun 1;102(11):882-92
  • Bedeir K, Bliden K, Tantry U, Gurbel PA, Mahla E. Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. Can J Cardiol.2016 Jun;32(6):724-5.
  • Bliden KP, Chaudhary R, Lopez LR, Damrongwatanasuk R, Guyer K, Gesheff MG, Franzese CJ, Kaza H, Tantry US, Gurbel PAOxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. Am J Cardiol. 2016 Jun 15.
  • Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PAProprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med.2016 May 3;164(9):600-7
  • Kwon TJ, Tantry US, Park Y, Choi YM, Ahn JH, Kim KH, Koh JS, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Smith SC Jr, Jeong YH. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost. 2016 May 2;115(5):979-92
  • Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PAExtended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascularevents. Expert Rev Cardiovasc Ther. 2016 May 23.
  • Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside.Circ Res. 2016 Apr 29;118(9):1380-91.
  • Bliden KP, Tantry US, Gesheff MG, Franzese CJ, Pandya S, Toth PP, Mathew DP, Chaudhary R, Gurbel PAThrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis.J Interv Cardiol. 2016 Apr;29(2):168-78.
  • Chaudhary R, Bliden KP, Tantry US, Mohammed N, Mathew D, Gesheff MG, Franzese CJ, Gurbel PA.Association of weight gain with coronary artery disease, inflammation and thrombogenicity. J Thromb Thrombolysis. 2016 Apr;41(3):394-403.
  • Gurbel PA, Jeong YH,Navarese EP, Tantry US. Platelet-Mediated Thrombosis: From Bench to Bedside.Circ Res. 2016 Apr 29;118(9):1380-91.
  • Gurbel PA, Tantry USDeciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. Eur Heart J. 2016 Apr 7;37(14):1143-4
  • King K, Grazette LP, Paltoo DN, McDevitt JT, Sia SK, Barrett PM, Apple FS, Gurbel PA, Weissleder R, Leeds H, Iturriaga EJ, Rao A, Adhikari B, Desvigne-Nickens P, Galis ZS, Libby P. Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci. 2016 Jan-Feb;1(1-2):73-86..
  • Gurbel PA, Tantry USCardioPulse: Platelet inhibitors and their differences. Eur Heart J. 2016 Jan 21;37(4):323-6
  • Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol.2016 Jan;36(1):189-97.